Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living ...
Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE® SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today …